- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 28.11. | Elicera Therapeutics AB: Elicera Therapeutics AB (publ) Interim Report 1 January - 30 September 2024 | 47 | GlobeNewswire (Europe) | Third quarter (July-September 2024)
Operating profit/loss amounted to SEK -2,697,267 (-5,149,440).
Loss for the period amounted to SEK -2,514,629 (-5,046,574).
Cash flow from operating activities... ► Artikel lesen | |
| 27.11. | ELICERA THERAPEUTICS: Elicera's CEO: "ELC-100 stands apart from all other standard treatments" | 1 | Cision News | ||
| 12.11. | ELICERA THERAPEUTICS: Elicera's CEO: "One of the biggest milestones in our history" | 1 | Cision News | ||
| ELICERA THERAPEUTICS Aktie jetzt für 0€ handeln | |||||
| 05.11. | Elicera Therapeutics includes the first patient in the Phase I/II clinical study CARMA targeting B-cell lymphoma | 1 | Cision News | ||
| 04.11. | Elicera Therapeutics will present at the BioStock Life Science Summit, November 20 | 5 | Cision News | ||
| 24.10. | Elicera Therapeutics enrolls the last patient in the clinical phase I/II-trial with oncolytic virus ELC-100 | 3 | Cision News | ||
| 03.09. | Elicera Therapeutics will participate in upcoming industry and investor conferences during the fall | 2 | Cision News | ||
| 29.08. | Elicera Therapeutics AB: Elicera Therapeutics AB (publ) Interim Report 1 January - 30 June 2024 | 18 | GlobeNewswire (Europe) | Second quarter (April-June 2024)
Operating profit/loss amounted to SEK -5,841,409 (-4 466 286).
Loss for the period amounted to SEK -5,622,779 (-4,335,852).
Cash flow from operating activities... ► Artikel lesen | |
| 27.05. | Elicera Therapeutics AB: Elicera Therapeutics AB (publ) Interim Report 1 January - 31 March 2024 | 332 | GlobeNewswire (Europe) | First quarter (January-March 2024)
Operating profit/loss amounted to SEK - 5,433,422 (-2,265,857).
Loss for the period amounted to SEK - 5,369,677 (-2,266,329).
Cash flow from operating activities... ► Artikel lesen | |
| 14.05. | Nasdaq Stockholm AB: Change of Certified Adviser for Elicera Therapeutics AB | 218 | GlobeNewswire | As from May 15, 2024, Elicera Therapeutics AB (publ) will change Certified
Adviser to Mangold Fondkommission AB.
This information is distributed at the request of the Certified Adviser,
Carnegie... ► Artikel lesen | |
| 04.04. | Nasdaq Stockholm AB: New equity right for trading, Elicera Therapeutics AB TO2 | 278 | GlobeNewswire | At the request of Elicera Therapeutics AB, Elicera Therapeutics AB equity
rights will be traded on First North Growth Market as from April 5, 2024.
Security name: Elicera Therapeutics AB TO2
-------------------------------------------
Short... ► Artikel lesen | |
| 27.03. | Nasdaq Stockholm AB: Last day of trading in paid subscription shares (BTU) of Elicera Therapeutics AB | 270 | GlobeNewswire | Trading in Elicera Therapeutics AB paid subscription units is to cease. The
last trading day is March 28, 2024.
Short name: ELIC BTU
ISIN code: SE0021626306
Orderbook ID: 324876
This information... ► Artikel lesen | |
| 23.02. | Nasdaq Stockholm AB: Listing of unit rights and paid subscription units of Elicera Therapeutics AB (91/24) | 566 | GlobeNewswire | With effect from February 26, 2024, the unit rights in Elicera Therapeutics AB
will be traded on First North Growth Market. Trading will continue up until and
including March 05, 2024.
Instrument:... ► Artikel lesen | |
| 19.02. | XFRA CAPITAL ADJUSTMENT INFORMATION - 19.02.2024 | 930 | Xetra Newsboard | Das Instrument CP6 US2166484020 COOPER COS INC. DL-,10 EQUITY wird cum Kapitalmassnahme gehandelt am 19.02.2024 und ex Kapitalmassnahme am 20.02.2024 The instrument CP6 US2166484020 COOPER COS INC.... ► Artikel lesen | |
| 13.02. | Elicera Therapeutics AB: Year-End Report 1 January - 31 December 2023 | 209 | GlobeNewswire (Europe) | Fourth quarter (October-December 2023)
Operating profit/loss amounted to SEK -5,212,694 (-3,951,799).
Loss for the period amounted to SEK -4,749,222 (-3,898,340).
Cash flow from operating... ► Artikel lesen |
15 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| EVOTEC | 8,405 | +1,08 % | Evotec Aktie: Beeindruckende Entwicklung! | Die Evotec-Aktie zeigt im aktuellen Börsenumfeld erste Anzeichen einer Stabilisierung. Nach einem herausfordernden Jahr 2024 mit einem Rückgang von fast 60 Prozent konnte sich das Papier zuletzt von... ► Artikel lesen | |
| REGENERON PHARMACEUTICALS | 675,00 | +0,21 % | Regeneron Pharma: Phase 3 Trial With EYLEA HD 8 Mg Meets Primary Endpoint | BRUSSELS/FRANKFURT/PARIS (dpa-AFX) - Regeneron Pharmaceuticals (REGN) announced the primary endpoint was met in the Phase 3 QUASAR trial investigating EYLEA HD or aflibercept injection 8 mg... ► Artikel lesen | |
| BRAIN BIOTECH | 3,530 | +2,02 % | AKTIONÄR-Tipp BRAIN Biotech: Große Ziele - Neubewertung nimmt Fahrt auf | In den zurückliegenden Monaten hat sich die Aktie von BRAIN Biotech an der Börse eindrucksvoll zurückgemeldet. Und auch auf dem heutigen Kapitalmarkttag hat das Unternehmen mit Sitz im hessischen Zwingenberg... ► Artikel lesen | |
| SCORPIUS | 0,330 | -12,81 % | Scorpius Holdings, Inc. - S-1, General form for registration of securities | ||
| CARDIOL THERAPEUTICS | 1,258 | +2,11 % | Insider Buying: Cardiol Therapeutics Inc. (TSE:CRDL) Senior Officer Purchases 10,000 Shares of Stock | ||
| BURCON NUTRASCIENCE | 0,055 | +5,38 % | Burcon NutraScience Corporation: Burcon Updates Rights Offering | Vancouver, British Columbia--(Newsfile Corp. - December 17, 2024) - Burcon NutraScience Corporation (TSX: BU) (OTCQB: BRCNF) ("Burcon" or the "Company"), a global technology leader in the development... ► Artikel lesen | |
| CSL | 167,64 | -0,02 % | Why CSL and these excellent ASX retirement shares could be buys in 2025 | ||
| MANNKIND | 6,700 | +2,35 % | MannKind Reports Encouraging 6-month Data From Phase 3 INHALE-1 Study | WASHINGTON (dpa-AFX) - MannKind Corporation (MNKD) Monday reported positive six-month results from its Phase 3 INHALE-1 study of Afrezza Inhalation Powder, a rapid-acting inhaled human insulin... ► Artikel lesen | |
| OCULAR THERAPEUTIX | 8,220 | +0,91 % | Ocular Therapeutix, Inc.: Ocular Therapeutix Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) | BEDFORD, Mass., Dec. 13, 2024 (GLOBE NEWSWIRE) -- Ocular Therapeutix, Inc. (NASDAQ:OCUL, "Ocular"), a biopharmaceutical company committed to improving vision in the real world through the development... ► Artikel lesen | |
| OXFORD NANOPORE TECHNOLOGIES | 1,790 | +1,47 % | Oxford Nanopore Tech - Directorate Change - Appointment of SID | ||
| ADAPTIMMUNE THERAPEUTICS | 0,585 | +0,86 % | Adaptimmune Therapeutics PLC: Adaptimmune Announces Changes to its Executive Leadership Team Based in The UK | Helen Tayton-Martin, Ph.D., M.B.A, Adaptimmune Co-Founder and Chief Business & Strategy Officer, will step down from the Company March 31, 2025Gavin Wood, Chief Financial Officer, will step down from... ► Artikel lesen | |
| CODEXIS | 5,060 | 0,00 % | Codexis, Inc.: Codexis Announces New Employment Inducement Grants | REDWOOD CITY, Calif., Dec. 06, 2024 (GLOBE NEWSWIRE) -- Codexis, Inc. (NASDAQ: CDXS), a leading provider of enzymatic solutions for efficient and scalable therapeutics manufacturing, today announced... ► Artikel lesen | |
| TELO GENOMICS | 0,089 | +14,94 % | Telo Genomics-Aktionäre aufgepasst: Könnte die Aktie am Montag komplett einbrechen - Das müssen Sie JETZT beachten! | ||
| BIORA THERAPEUTICS | 1,260 | 0,00 % | XFRA DELETION OF INSTRUMENTS FROM BOERSE FRANKFURT - 16.12.2024 | The following instruments on Boerse Frankfurt do have their last trading day on 16.12.2024Die folgenden Instrumente in Boerse Frankfurt haben ihren letzten Handelstag am 16.12.2024ISIN NameAU0000201006 HYGROVEST... ► Artikel lesen | |
| CORMEDIX | 8,350 | +1,21 % | CorMedix, Inc.: CorMedix Inc. Added to Nasdaq Biotechnology Index | BERKELEY HEIGHTS, N.J., Dec. 19, 2024 (GLOBE NEWSWIRE) -- CorMedix Inc. (Nasdaq: CRMD), a biopharmaceutical company focused on developing and commercializing therapeutic products for life-threatening... ► Artikel lesen |
ELICERA THERAPEUTICS AB gehört der Branche Biotechnologie an. Der aktuelle Kurs liegt bei 0,123 Euro und damit +3,81 % im Plus.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu ELICERA THERAPEUTICS AB finden Sie auf Wallstreet Online.
